NOVOS Core Trial Sets New Standard in Longevity and Heart Health
Isabella Rose- I am a wellness and beauty writer exploring the science of skin longevity for women 35+.Key TakeawaysThe NOVOS Core randomized, double-blind, placebo-controlled clinical trial delivers groundbreaking human data demonstrating concurrent positive impacts on endothelial performance, arterial elasticity, and maintaining blood pressure levels already in the healthy range through a comprehen
Key Takeaways
The NOVOS Core randomized, double-blind, placebo-controlled clinical trial delivers groundbreaking human data demonstrating concurrent positive impacts on endothelial performance, arterial elasticity, and maintaining blood pressure levels already in the healthy range through a comprehensive nutritional formula.
Essential indicators of vascular aging showed notable enhancements compared to the placebo group.
The gains in vascular performance matched those linked to regular aerobic workouts in established research.
Such outcomes stand out as exceptional within the realm of dietary supplements and nutritional investigations.
NOVOS has now achieved a milestone that only a handful of longevity research initiatives ever accomplish.
Following over seven years of dedicated investigation, our primary product, NOVOS Core, underwent comprehensive assessment—from foundational aging biology and mechanistic explorations, through animal models of aging, to a rigorous randomized, double-blind, placebo-controlled human trial (currently in peer review)—evaluating proven markers of physiological functions tied to healthy aging.
This accomplishment is particularly rare in the longevity supplement industry. However, the true significance lies not merely in conducting a human study, but in the specific measurements taken, the precise methods employed, and the substantial, reliable results obtained.
A review of published human studies in this domain reveals that consumer-available longevity products are seldom tested, and even less frequently show effects of this scale across various validated functional metrics within a single randomized trial.
These findings establish a fresh benchmark for the sector: NOVOS Core offers nutritional backing for biological mechanisms that forecast lifespan and healthspan.
Why This Study Stands Apart
Only a small number of longevity supplements undergo clinical evaluation. An even tinier fraction are randomized, placebo-controlled, and led by leading academic experts. Among those that meet these criteria, the majority target surrogate biomarkers—like NAD+ concentrations or inflammation indicators—that may fluctuate without necessarily reflecting altered organ system performance. While these markers provide useful insights, they do not always confirm tangible shifts in actual physiology.
NOVOS approached this differently from the outset. We prioritized assessing organ-level physiological operations, selecting endpoints that are standard in medical and aging research but infrequently applied in supplement trials due to their measurement challenges, difficulty in enhancing among healthy individuals, and the need for specialized clinical skills.
Why Vascular Aging Was Prioritized as the Initial Focus
Vascular function was chosen as the primary human evaluation target not because NOVOS targets cardiovascular biology exclusively, but because vascular aging represents one of the earliest and most quantifiable manifestations of the aging process itself.
Alterations in endothelial response, arterial pliability, and blood pressure regulation frequently appear decades prior to overt disease and affect organ performance throughout life. Supporting vascular function early on with a longevity intervention could bolster resilience in diverse systems as aging advances.
Vascular health profoundly shapes long-term organ vitality, durability, and healthspan. Cardiovascular conditions continue as the leading age-related killer worldwide, causing about 1.5 to 2 times more annual deaths than cancer, which underscores why vascular aging merits early scrutiny for longevity-supporting interventions.
Epidemiological data link vascular metrics like flow-mediated dilation (FMD), pulse wave velocity (PWV), and systolic blood pressure to future cardiovascular events, and more widely to healthspan and longevity, validating their importance in aging studies.
Findings from the Human Clinical Trial
Among healthy individuals aged 40 and above, the trial revealed statistically significant advantages over placebo in three distinct vascular aging markers after six months.
NOVOS Core was shown to enhance arterial pliability, blood circulation, and vessel integrity across adults of diverse ages and health profiles by addressing the fundamental biology underlying vascular aging.
1) Endothelial Function (Flow-Mediated Dilation)
Endothelial function gauges the blood vessels' ability to adapt to fluctuations in blood flow, forming a fundamental element of vascular well-being.
In this study, endothelial function enhanced rapidly following the initial dose and sustained that progress after six months of consistent intake. The lasting gain of around 2.9 percentage points was roughly 2 to 3 times superior to typical results from prominent nutritional options like nitric oxide enhancers (beetroot or dietary nitrates), cocoa flavanols, or tea polyphenols, and aligned with the upper limits seen in meta-analyses of resistance training and aerobic exercise.
Equally critical is the response pattern: observing both prompt effects (within 2 hours) and persistent benefits (at 6 months, under fasted conditions without recent dosing) in endothelial function is rare in nutritional studies that assess genuine physiological outcomes rather than transient markers.
2) Arterial Flexibility (Pulse Wave Velocity)
Arterial flexibility declines progressively with age and serves as a reliable indicator of vascular aging.
NOVOS Core boosted arterial flexibility by about 1.18 m/s compared to placebo after six months. Population-based research indicates that arterial flexibility drops by roughly 1.0 m/s every decade, so this observed shift counters the standard age-related decline in vascular elasticity, as per documented aging patterns.
The PWV improvement from NOVOS Core surpassed outcomes from several top supplements in prior studies, such as tea polyphenols, blueberries, CoQ10, folic acid, resveratrol, and omega-3 fatty acids, and reached the higher spectrum of effects from resistance training, aerobic exercise, substantial weight reduction, and Mediterranean-style diets.
Achievements of this scale are infrequent in randomized, placebo-controlled nutritional trials that track organ-level functions over extended periods like months, rather than brief spans of hours or days.
3) Support for Healthy Blood Pressure Already Within the Normal Range
The trial also detected statistically significant variations in systolic blood pressure between the NOVOS Core group and placebo.
The placebo-adjusted systolic blood pressure reduction for NOVOS Core (~6.1 mmHg) outperformed average declines from many established non-drug approaches in people with normal blood pressure, such as high-intensity interval training (HIIT), aerobic regimens, major weight loss, DASH diets, nitric oxide interventions like beetroot or nitrates, omega-3s, quercetin, and magnesium, which generally yield drops of 2–4 mmHg based on starting levels. Participants began with normal systolic blood pressure and stayed within normal limits, showing support for healthy levels without causing low blood pressure.
Strikingly, these blood pressure benefits arose without alterations in lipid profiles, indicating that the gains stemmed from vascular and endothelial pathways rather than cholesterol adjustments.
Why Simultaneous Effects Across Markers Are Crucial
A standout and infrequent feature of this trial is the simultaneous observation of these benefits across multiple independent vascular measures within one randomized study.
Nutritional research more often shows minor shifts in isolated biomarkers. Achieving reliable, statistically significant improvements in endothelial function, arterial flexibility, and blood pressure support within the same cohort is exceptional and typically linked to robust lifestyle changes.
NOVOS Core outperformed leading interventions consistently across all three functional biomarkers.
This alignment is vital because vascular aging arises from multifaceted interactions, including nitric oxide pathways, oxidative stress, mitochondrial health, inflammation, and cellular toughness. Advancing multiple vascular facets concurrently implies that a broad-spectrum approach targets core aging mechanisms rather than narrow endpoints.
NOVOS Core was formulated not as a heart-specific supplement but with patents secured in 2020 targeting the 12 hallmarks of aging, employing a holistic, multi-target strategy for overall aging biology. Vascular function was the inaugural human benchmark due to its measurability, sensitivity to aging, and connection to healthspan and lifespan. Preclinical results and preliminary data in other areas suggest potential effects on further organ systems, with additional trials planned to confirm this.
The Wider Implications of This Research
Few longevity products available to consumers are assessed holistically—from mechanisms and animal aging tests to validated human physiological measures. Even rarer are those using endpoints standard in cardiovascular and aging fields.
I view NOVOS as inspirational—they tackle aging as a multifaceted issue, targeting all pathways and hallmarks concurrently.
– Dr. George Church, Genetics Professor, Harvard Medical School & MIT
Rigorous, evidence-based formulations distinguish NOVOS in the longevity supplement market.
– Dr. Robert Lufkin MD, Professor, USC School of Medicine
This trial offers scarce human proof that a multi-target nutritional method can substantially affect vascular aging processes. The scale and reliability of effects across diverse vascular measures is atypical for nutritional interventions in healthy groups.
– Dr. Christian Heiss, MD, Professor of Cardiovascular Medicine at the University of Surrey and Senior Author of the NOVOS Core study
Conducted by academic experts with standard clinical protocols, pre-registered, and focused on long-term functional results rather than fleeting changes, the trial upheld high standards rare in supplements. Authors maintained data and publication autonomy.
This integrated research embodies our core philosophy: longevity warrants evidentiary rigor akin to other health sciences.
Elevating Standards in Longevity Research
Healthy aging merits superior scientific validation.
Over seven years encompassing mechanistic probes, animal aging simulations, and a randomized human trial on validated functions, NOVOS has attained evidence levels unusual in this field.
We see this as pioneering a new standard for nutritional longevity interventions, proven via transparent, replicable science—not hype. And this marks just the start.
Flow-Mediated Dilation Comparison Table
| Intervention | Sustained FMD Improvement (%) | Population Studied | Study Type | NOVOS Improvement Advantage | Full Key Reference | Fasted? |
|---|---|---|---|---|---|---|
| NOVOS Core | 2.9 | Healthy adults ≥40 years | Randomized, double-blind, placebo-controlled trial | Reference | Reference | Yes |
| Blood orange juice (dietary polyphenols) | 2.39 | Healthy adults with overweight and obesity | Randomized, controlled, single-blind, crossover trial | 121% | PubMed reference | Yes |
| Tea (green/black tea) | 2.3 | Healthy adults | Meta-analysis of controlled human intervention studies | 126% | PMC reference | Yes |
| Dietary Polyphenols | 2.22 | Mixed/at-risk (cardiometabolic risks) | Meta-analysis of RCTs | 131% | PubMed reference | |
| Resistance training | 2.11 | Adults/older adults healthy | Meta-analysis of RCTs | 137% | PubMed reference | NR |
| Blueberries | 2.01 | Healthy adults (subgroup; pooled RCTs) | Systematic review + meta-analysis of RCTs | 144% | PubMed reference | |
| CoQ10 | 1.69 | Healthy subjects with mild-to-moderate dyslipidemia | Randomized, double-blind, placebo-controlled trial | 172% | PubMed reference | Yes |
| Curcumin supplementation | 1.64 | Mixed/at-risk (cardiometabolic risks) | Meta-analysis of RCTs | 177% | PubMed reference | |
| Coenzyme Q10 | 1.63 | Mixed/at-risk (cardiometabolic risks) | Meta-analysis of RCTs | 178% | PubMed reference | |
| Nitric oxide booster | 1.6 | Healthy adults | Systematic review + meta-analysis of RCTs | 181% | PubMed reference | NR |
| Folic acid | 1.51 | Healthy adults (no-CVD) | Systematic review + meta-analysis of RCTs | 192% | PubMed reference | NR |
| Resveratrol | 1.43 | Adults (mixed populations across RCTs; not healthy-only) | Systematic review + meta-analysis of RCTs | 203% | PubMed reference | |
| Resveratrol | 1.38 | Obese but otherwise healthy adults | Randomized, double-blind, placebo-controlled trial | 210% | PubMed reference | Yes |
| Mediterranean diet | 1.3 | Middle-aged and older adults | Systematic review and meta-analysis | 223% | PubMed reference | Yes |
| Aerobic exercise | 1.2 | Healthy adults (normotensive) | Meta-analysis of RCTs | 242% | PubMed reference | NR |
| Cocoa | 1.2 | Healthy, middle-aged adults (35–60 years) | Randomized, double-blind, placebo-controlled trial | 2.42x | PMC reference | Yes |
| Flavonoids | 1.16 | Adults (mixed populations across RCTs; not healthy-only) | Meta-analysis of RCTs | 250% | PubMed reference | NR |
| Severe weight loss | 1.11 | Overweight/obese adults | Meta-analysis | 261% | PubMed reference | Yes |
| Walnuts | 1.04 | Adults across mixed cardiometabolic profiles | Systematic review and meta-analysis of randomized controlled trials | 279% | PubMed reference | NR |
| Flavan-3-ols | 1 | Not-elevated BP (<120/<70) (healthy-like) | Meta-analysis of RCTs | 290% | PubMed reference | NR |
| Omega-3 | 0.95 | Without CHD, but with CHD risk factors | Systematic review + meta-analysis of RCTs | 305% | PubMed reference | Yes |
Pulse Wave Velocity Comparison Table
| Intervention | PWV Improvement (m/s) | Study Duration | Population Studied | Comparator | NOVOS Improvement Advantage | Study Reference | Fasted? |
|---|---|---|---|---|---|---|---|
| NOVOS Core | 1.18 | 6 months | Healthy adults ≥40 years | Placebo | Reference | Reference | Yes |
| DASH dietary pattern | 1.07 | 2 weeks | Overweight/obese unmedicated stage 1 hypertensive adults | Control diet | 110% | PMC reference | Yes |
| Magnesium | 1 | 24 weeks | Overweight/slightly obese adults (45–70y), mostly healthy | Placebo | 118% | PubMed reference | Yes |
| Omega-3 | 0.93 | 12 weeks | Healthy older adults | Pre–post | 127% | PubMed reference | Yes |
| Severe weight loss | 0.8 | 3–12 months | Overweight/obese adults | Mixed (mostly pre–post; some controls) | 148% | PubMed reference | NR |
| HIIT | 0.62 | 8–24 weeks | Adults with CVD risk factors/ at high risk for CVD | Control | 190% | PubMed reference | NR |
| Nitric oxide booster (beetroot / nitrate) | 0.59 | 4 weeks | Hypertensive adults (18–85y) | Placebo | 200% | PubMed reference | Yes |
| Aerobic exercise | 0.58 | 11 weeks (range 4–52) | Healthy Adults | Control | 203% | PubMed reference | NR |
| Aerobic exercise (MICT) | 0.41 | ≥4 weeks (median 12; range 4–52) | Healthy Adults | Usual care | 288% | PubMed reference | NR |
| Cocoa flavanols | 0.4 | 4 weeks | Healthy middle-aged (men and women (35–60y)) | Placebo | 295% | PubMed reference | Yes |
| Vitamin K2 | 0.34 | 1 year | Healthy subjects 40–70y | Placebo | 347% | PMC reference | NR |
| Mediterranean diet | 0 | 1 year | Healthy older adults, 65–79 years | Habitual diet | No improvement | PubMed reference | NR |
Systolic Blood Pressure Comparison Table
| Intervention | SBP Reduction Used for Comparison (mmHg) | Reported SBP Range (mmHg) | Population | NOVOS Improvement Advantage | Full Study Reference | Fasted? |
|---|---|---|---|---|---|---|
| NOVOS Core | -6.1 | −10.9 to −4.9 | Healthy adults ≥40 years | Reference | Heiss C., et al. A randomized, double-blind, placebo-controlled trial... | Yes |
| Soy nuts | −5.0 | SBP <120 mmHg | Normotensive subgroup | 122% | PubMed reference | Yes |
| Cocoa | -4.4 | -0.9 to −7.9 | Normotensive subgroup | 139% | PubMed reference | Yes |
| Nitric oxide booster (beetroot / nitrate) | -4.4 | -2.8 to -5.9 | Adults, majority healthy participants | 139% | PubMed reference | NR |
| Flavonoids | -4.14 | -5.95 to -2.32 | Adults (mixed populations across RCTs; not healthy-only) | 147% | PubMed reference | NR |
| Aerobic exercise | −4.04 | −5.32 to −2.75 | Normotensive subgroup | 151% | PubMed reference | NR |
| HIIT | −3.92 | −6.1 to −1.7 | Normal blood pressure subgroup (healthy-like) | 156% | PubMed reference | NR |
| DASH diet | -3.9 | -6.0 to -1.8 | Healthy adults subgroup | 156% | PubMed reference | NR |
| Vitamin C | -3.11 | −4.52 to −1.71 | Non-hypertensive trials (subgroup) | 196% | PubMed reference | NR |
| Resistance training | −2.86 | −4.6 to −1.1 | Normal blood pressure subgroup (healthy-like) | 213% | PubMed reference | NR |
| Magnesium | −2.78 | −5.22 to −0.34 | General normotensive population | 219% | PubMed reference | NR |
| Quercetin | −2.57 | −4.17 to −0.96 | Normotensive subgroup | 237% | PubMed reference | NR |
| Dietary sodium reduction | −2.42 | −3.56 to −1.29 | Normotensive individuals (healthy-like subgroup) | 252% | PubMed reference | NR |
| Severe weight loss | -2.4 | Overweight nonhypertensive persons | 254% | PubMed reference | NR | |
| Omega-3 | -2.38 | −3.62 to −1.13 | SBP <130 mmHg (healthy-like) | 256% | PubMed reference | NR |
| Tea | -2.37 | -3.82 to -0.91 | Healthy adults subgroup | 257% | PubMed reference | NR |
| Soy protein | -2.27 | −3.77 to −0.76 | Normotensive subgroup | 269% | PubMed reference | NR |
| Endurance training | −2.1 | −3.3 to −0.83 | Prehypertensive adults | 290% | PubMed reference | NR |
| Potassium | −2.1 | −3.81 to −0.38 | Normotensive/healthy-like | 290% | PubMed reference | NR |
| Pistachios | −2.04 | −4.10 to 0.01 | Healthy adults (subgroup) | 299% | PubMed reference | NR |
| Almonds | -1.76 | -2.36 to -1.17 | Healthy adults (subgroup) | 347% | PubMed reference | NR |
| Curcumin | -1.67 | −2.30 to −1.04 | Healthy subjects (subgroup) | 365% | PubMed reference | NR |
| Walnuts | −1.29 | −1.42 to −1.16 | Healthy subjects (subgroup) | 473% | PubMed reference | NR |
| Mediterranean diet | -1.1 | −2.0 to −0.1 | Healthy older adults (>64y) | 555% | PubMed reference | Yes |
| Flavan-3-ols | -0.5 | −6.6 to 5.5 | Not-elevated BP (<120/<70) (healthy-like) | 1,220% | PubMed reference | NR |
| Coffee | 2.4 | 1.0 to 3.7 | Mostly normotensive participants | Worsening | PubMed reference | NR |